Phase II study of fosfluridine tidoxil in an oral multiple dose schedule given once-a-day for 7 consecutive days every 2 weeks in patients with advanced breast and colorectal cancer

Primary objectives: To determine the objective tumour response rate (complete and partial response of target lesions) in patients diagnosed with advanced breast or colorectal cancer after three complete cycles of treatment with fosfluridine tidoxil
Primary endpoints: Objective tumour response rate on target lesions.
At least one, but not more than ten target lesions, as identified prior to the first administration of study drug will be measured and the sum of the longest diameter of target lesions will be calculated. The percentage change in the sum of the longest diameter of the target lesions will be calculated